PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Coverage · Medical Policy · PA · Dermatology, Plastic Surgery, General SurgeryMedium impact

11.08.04i, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)

Act
by Apr 1, 2026, the billing team must
Effective date
Apr 1, 2026
Identified
Jun 19, 2026

Summary

Independence Blue Cross reissued Policy 11.08.04i on 04/01/2026 reaffirming its continuing position on PDL treatment coverage. The policy clarifies medically necessary indications (port wine stains, hemangiomas, hypertrophic/keloidal scars, pyogenic granulomas, viral warts, and rosacea), designates specific conditions as experimental/investigational (psoriasis, molluscum contagiosum, basal cell carcinoma, cutaneous lupus), and updates rosacea treatment criteria to require 6-month failed medical management before PDL coverage. Billing teams must verify patient diagnoses against the expanded ICD-10 code list and confirm medical necessity documentation for rosacea cases.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Apr 1, 2026, the billing team must · 6 steps
01Update claim denial logic to automatically reject PDL claims (CPT 17000, 17003, 17004, 17106, 17107) with experimental/investigational diagnosis codes B08.1, C44.01-C44.91, D86.3, L40.0-L40.9, or L93.1.
02For rosacea claims (L71.1, L71.8, L71.9), require documentation in the patient record proving 6-month failed medical management with topical treatments (sodium sulfacetamide, antibiotics, azelaic acid, or α-adrenergic agonists) before claim submission.
03Update encounter forms and EMR templates to flag rosacea cases for documentation review.
04Train providers and front desk staff that PDL is not covered for psoriasis, molluscum contagiosum, basal cell carcinoma, or cutaneous lupus.
05Claims lacking the required 6-month treatment history documentation will be denied.
06Verify all active PDL orders against the medically necessary diagnosis code list (A63.0, B07.0-B07.9, D18.01, D18.09, L92.8, L98.0, L91.0, L71.1, L71.8, L71.9, L90.5, Q82.5) to ensure compliance.

Codes mentioned

1700017003170041710617107A63.0B07.0B07.8B07.9B08.1C44.01C44.111C44.1121C44.1122C44.1191C44.1192C44.211C44.212C44.219C44.310C44.311C44.319C44.41C44.510C44.511C44.519C44.611C44.612C44.619C44.711C44.712C44.719C44.81C44.91D18.01D18.09D86.3L40.0L40.8L40.9L71.1L71.8L71.9L90.5L91.0L92.8L93.1L98.0Q82.5

Original notice

11.08.04i, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account